TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04322786
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any prescription of ACE inhibitor
Study: NCT02912455
Drug: Placebo (for canagliflozin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
Study: NCT00915915
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
Study: NCT00915915
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
Study: NCT01845337
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00130026
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg IV
Study: NCT03333408
Drug: Postoperative Oral Antibiotics (Clindamycin or Augmentin)
Normalized name: clindamycin Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive postoperative oral antibiotics (Clindamycin or Augmentin) for 10-14 days upon discharge.
Study: NCT04505202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients included in the placebo group ( sodium bicarbonate) will receive 3 times daily oral care
Study: NCT03725033
Drug: Subetta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT03725033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT00649363
Drug: Zofran ODT® Tablets 8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg, single dose fasting
Study: NCT02237235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
Study: NCT00336843
Drug: Zevalin-BuCyE
Approvals — FDA: no, EMA: no, PMDA: no
Description: rituximab (IV, 250 mg/m2 on days -21 and -14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day -14) Busulfan (IV, 0.8 mg/kg every 6 h from day -7 to day -5) Cyclophosphamide (IV, 50 mg/kg on days -3 and -2) Etoposide (IV, 200 mg/m2 every 12 h on days -5 and -4) Autologous stem cells infusion on day 0
Study: NCT04294251
Drug: DWP450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
Study: NCT04294251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
Study: NCT04192656
Drug: Ginaton
Normalized name: Genaton
Approvals — FDA: no, EMA: no, PMDA: no
Description: ginnaton is ginkgo biloba extract
Study: NCT03779178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo perfusion is sodium chloride NaCl 0.9% over 120 minutes in incremental doses : 0.03, 0.06, 0.12, 0.3 and 0.6 mL/kg/h. Doses are modified every 20 minutes. Perfusion are similar in landiolol group to preserve blind.
Study: NCT02690519
Drug: GLPG1837 dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
Study: NCT02690519
Drug: GLPG1837 dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
Study: NCT02352987
Drug: Neem plus propylene glycol plus salicylic acid
Normalized name: propylene glycol salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
Study: NCT02450552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT02710305
Drug: oral placebo tablets plus placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
Study: NCT02412904
Drug: HMG
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
Study: NCT00835328
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: A short-term intravenous infusion of normal saline (0.9% NaCl), or the vehicle, will be administered over up to 9 hours.
Study: NCT01288092
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00770133
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of vehicle ophthalmic solution at visit 3 and visit 4.
Study: NCT01142193
Drug: USL255
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03396484
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral dosing
Study: NCT00649051
Drug: Zaroloxyn® Tablets 2.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4x2.5mg, single dose fasting
Study: NCT01554176
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, one tablet, orally, once daily at bedtime
Study: NCT02664922
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
Study: NCT05287425
Drug: Gentamicin Ophthalmic
Normalized name: gentamicin ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops daily in both eyes for 7 ± 1 days
Study: NCT01134601
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01492686
Drug: MCI-186
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study: NCT01492686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Study: NCT00079638
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00079638
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03244462
Drug: BAY1834845
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (IR \[immediate release\] tablets)
Study: NCT03244462
Drug: BAY1834845
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.v. infusion of \[13C6\]-labeled BAY1834845
Study: NCT00981747
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill three times per day for 3 months followed by a one month washout prior to next intervention.
Study: NCT02678000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of LHW090
Study: NCT02604173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill and sham inhaler
Study: NCT00691873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02153229
Drug: Photofrin 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
Study: NCT00223730
Drug: Citrulline
Normalized name: Citrulline
DrugBank: Citrulline (DB00155)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
Study: NCT00223730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00741585
Drug: Any antihypertensive medication alone or in combination
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: All drugs on awakening
Study: NCT00741585
Drug: Any antihypertensive medication alone or in combination
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or more drugs at bedtime
Study: NCT00308321
Drug: long term tapering of prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
Study: NCT00308321
Drug: standard prednisolone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
Study: NCT00388297
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
Study: NCT00388297
Drug: Placebo for Levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02507843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in placebo group monthly for 6 months.
Study: NCT04478500
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomly assigned to receive either Minocycline 100mg twice daily or Placebo.~Comprehensive testing will be performed at baseline, and at the end of the 12 week intervention phase.
Study: NCT00648505
Drug: Metaglip® Tablets 5 mg/500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5/500mg, single dose fed
Study: NCT03126864
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/m2 administered by vein on Day -3.
Study: NCT03114657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered by intravenous (IV) infusion at 60mg/kg as per the dosing schedule described above.
Study: NCT00396877
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: reconstituted solution using matching placebo powder~Route: oral or enteric~Frequency: once daily~Dose: daily dose adjusted for weight
Study: NCT03531892
Drug: AJM300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AJM300 film-coated tablets.
Study: NCT03531892
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to AJM300 tablets.
Study: NCT01858909
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration via oral or via a nasogastric tube followed by 20mL saline
Study: NCT04086342
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a vehicle oil that will match CHI-902.
Study: NCT04023266
Drug: Intravenous N-Acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetyl cysteine bolus and infusion as described in the experimental arm.
Study: NCT01295567
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: prior to CABG surgery 3 day treatment with placebo capsules twice daily
Study: NCT02470403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT00704548
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin once daily, orally in the morning period, during eigth weeks
Study: NCT00704548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily, orally in the morning period, during eigth weeks
Study: NCT02329301
Drug: Focal MDA with DHAp (Eurartesim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurartesim is the brand name.
Study: NCT01078051
Drug: optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimal medical therapy
Study: NCT02607657
Drug: Eplerenone 25 mg
Normalized name: eplerenone 25 MG
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02607657
Drug: Eplerenone 50 mg
Normalized name: eplerenone 50 MG
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02607657
Drug: Eplerenone 100 mg
Normalized name: eplerenone 100 MG
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02607657
Drug: Eplerenone 50 mg twice a day
Normalized name: eplerenone 50 MG
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02607657
Drug: Eplerenone 25 mg twice a day
Normalized name: eplerenone 25 MG
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02301286
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001300
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03091075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group will receive placebo for 12 weeks postoperative
Study: NCT00711607
Drug: nomegestrol acetate and estradiol
Normalized name: nomegestrol and estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
Study: NCT04016246
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
Study: NCT00030420
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
Study: NCT04167995
Drug: Probiotic Formula lacteal forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator: Patient with attention deficit hyperactive disorder patients (n=40) will receive probiotic preparation twice daily (Lacteol Forte; Rameda, Egypt) as sachets containing 10 billion colony forming units (CFU) of Lactobacillus fermentum and Lactobacillus delbruekii for 12 weeks .
Study: NCT03444298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each dose consists of two capsules by mouth once daily for a total of 7 days.
Study: NCT02942771
Drug: 0.075mg/kg TT301/MW189
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg/kg IV twice daily on Days 1 through 5
Study: NCT02942771
Drug: 0.30mg/kg TT301/MW189
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg IV twice daily on Days 1 through 5
Study: NCT02942771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride
Study: NCT00085098
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 1 hour
Study: NCT01962545
Drug: OAC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single APT with either aspirin or clopidogrel is discontinued in this arm.
Study: NCT04499105
Drug: Mesenchymal Stem Cell + NaCl 0,9% 2ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients enrolled in Cipto Mangunkusumo Hospital with degenerative disc disease with no promising result after conventional treatment.
Study: NCT01153620
Drug: Lavasept 0.04%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.~Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.~Treatment Duration 60 minutes
Study: NCT01949103
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005808
Drug: photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo laser therapy
Study: NCT03835013
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 0.9% saline
Study: NCT01028261
Drug: ZGN-433
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
Study: NCT01496170
Drug: MK-8931
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
Study: NCT00003086
Drug: CAF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003086
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003086
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003086
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00868699
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT01496170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, orally, once per day for 7 days
Study: NCT01929707
Drug: LY3050258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01929707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00106639
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg twice daily
Study: NCT00106639
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg twice daily
Study: NCT03380507
Drug: Triple therapy group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refer to arms description
Study: NCT02423707
Drug: ALK Alutard Birch and/or 5-grasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.~The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use.
Study: NCT01054118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension and placebo capsule administered as single doses
Study: NCT03517618
Drug: S-1+leucovorin
Normalized name: (S)-Leucovorin
DrugBank: (6R)-Folinic acid (DB03256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive TS-1 orally 40-60 mg (depending on patient's body surface area (BSA)) in combination with calcium folinate 30 mg twice a day for 7 days in a 2-week cycle.~The treatment will be administered until disease progression, intolerable toxicity, or consent withdrawal during any time of the study.
Study: NCT00424502
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg po/week
Study: NCT01159600
Drug: Placebo identical to BI 10773 low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching BI 10773 low dose
Study: NCT01159600
Drug: Placebo identical to BI 10773 high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching BI 10773 high dose
Study: NCT04536961
Drug: Reference Treatment- BMS-986165-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT01047722
Drug: Aspirin ingestion followed by doing a Bleeding Volume Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
Study: NCT01811459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO or IV
Study: NCT05248724
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml of 0.9 saline
Study: NCT00553488
Drug: Regular insulin (Humulin)
Normalized name: insulin isophane / insulin, regular, human Pen Injector [Humulin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
Study: NCT04062123
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in this group will receive a intravenous infusion of this drug, during a portion of the study. Dose will be targeted to a brain effect site concentration of 0.9 ng/ml, using pharmacokinetic modelling within the STANPUMP algorithm that accounts for subject's age, gender, height, \& weight.
Study: NCT04062123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid IV solution will be infused, with no active drug.
Study: NCT00483704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets